共 50 条
miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein
被引:1
|作者:
Tonouchi, Erina
[1
,2
]
Gen, Yasuyuki
[1
]
Muramatsu, Tomoki
[1
]
Hiramoto, Hidekazu
[1
]
Tanimoto, Kousuke
[3
]
Inoue, Jun
[1
]
Inazawa, Johji
[1
,4
]
机构:
[1] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan
[2] Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Tokyo, Japan
[3] TMDU, Med Res Inst, Genome Lab, Tokyo, Japan
[4] Tokyo Med & Dent Univ, Bioresource Res Ctr, Bunkyo Ku, Tokyo, Japan
来源:
关键词:
BET BROMODOMAIN INHIBITORS;
SELECTIVE-INHIBITION;
LUNG-CANCER;
PROTEINS;
EGFR;
ADENOCARCINOMA;
RESISTANCE;
MUTATIONS;
CHROMATIN;
MICRORNAS;
D O I:
10.1038/s41598-018-22767-y
中图分类号:
O [数理科学和化学];
P [天文学、地球科学];
Q [生物科学];
N [自然科学总论];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
Bromodomain Containing 4 (BRD4) mediates transcriptional elongation of the oncogene MYC by binding to acetylated histones. BRD4 has been shown to play a critical role in tumorigenesis in several cancers, and the BRD4-NUT fusion gene is a driver of NUT midline carcinoma (NMC), a rare but highly lethal cancer. microRNAs (miRNAs) are endogenous small non-coding RNAs that suppress target gene expression by binding to complementary mRNA sequences. Here, we show that miR-3140, which was identified as a novel tumor suppressive miRNA by function-based screening of a library containing 1090 miRNA mimics, directly suppressed BRD4 by binding to its coding sequence (CDS). miR-3140 concurrently downregulated BRD3 by bind to its CDS as well as CDK2 and EGFR by binding to their 3' untranslated regions. miR-3140 inhibited tumor cell growth in vitro in various cancer cell lines, including EGFR tyrosine kinase inhibitor-resistant cells. Interestingly, we found that miR-3140 downregulated the BRD4-NUT fusion protein and suppressed in vitro tumor cell growth in a NMC cell line, Ty-82 cells. Furthermore, administration of miR-3140 suppressed in vivo tumor growth in a xenograft mouse model. Our results suggest that miR-3140 is a candidate for the development of miRNA-based cancer therapeutics.
引用
收藏
页数:13
相关论文